Skip to content

Assessment of the Bioavailability of Iron in Iron Fortified Bouillon Cubes in Healthy Nigerian Women

Assessment of the Bioavailability of Iron in Iron Fortified Bouillon Cubes in Healthy Nigerian Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02815449
Enrollment
24
Registered
2016-06-28
Start date
2017-05-08
Completion date
2017-07-24
Last updated
2017-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia

Keywords

Iron fortification, Bioavailability, Nigeria, Women, Bouillon cubes

Brief summary

The prevalence of iron deficiency anemia is a wide spread problem in Africa and iron fortification can be an effective strategy to decrease this. In the current study adding different levels of a stabilizer to iron fortified cubes and it's effect on iron bioavailability from these cubes will be studied in the context of a Nigerian meal in women. 24 Female subjects with low serum ferritin levels will be included in the study. The study will last 64 days and subjects will be asked to consume a breakfast and lunch prepared with a bouillon cube with isotope labeled iron during 3 periods of 5 consecutive days. The absorption of iron will be evaluated after every period and compared between the cubes.

Interventions

OTHERMeals prepared with iron fortified cube with Low stabilizer level

Meals prepared with iron fortified cube with Low stabilizer level

OTHERMeals prepared with iron fortified cube with Medium stabilizer level

Meals prepared with iron fortified cube with Medium stabilizer level

OTHERMeals prepared with iron fortified cube with High stabilizer level

Meals prepared with iron fortified cube with High stabilizer level

Sponsors

Obafemi Awolowo University
CollaboratorOTHER
Unilever R&D
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy female Nigerian subjects; * Age \> 18 and \<40 years at screening; * Body weight \<65 kg; * Apparently healthy: no medical conditions which might affect study measurements (judged by study physician); * With iron deficiency judged by a serum ferritin concentration of \<15µg/L; * Reported intense sporting activities ≤ 10h/w; * Reported alcohol consumption ≤ 14 units/w; * Willing and able to participate in the study; * Having given a written informed consent.

Exclusion criteria

* Being an employee of Unilever or the Department of Family, Nutrition and Consumer Science of the Obafemi Alowolo University; * Blood donation or significant blood loss over the past 6 months; * Being severely anemic (hemoglobin \< 8.0 g/dL) * Reported use of any medically- or self-prescribed diet; * Use of vitamin or mineral supplements and unwillingness to discontinue their use one week prior the study and during the study; * Smoking or consuming tobacco in any form, and/or was smoking or consuming tobacco in any form for 6 months preceding the study and/or will be smoking or consuming tobacco in any form, during the study; * Is pregnant or will be planning pregnancy during the study period; * Is lactating or has been lactating in the 6 weeks before pre-study investigation and/or during the study period; * Known gastrointestinal (including helminth infection) or metabolic disorders; * Participation in another clinical trial during the last 30 days prior to the beginning of the study; * Symptomatic malaria (no blood smear analyses on malaria required)

Design outcomes

Primary

MeasureTime frameDescription
Iron isotopic composition of the blood at the end of each intervention period16 daysThe amount of iron isotopic label in the blood will be related to the low, medium and high stabilizer level in the cubes to determine whether a dose-response relationship exists.

Secondary

MeasureTime frameDescription
Iron isotopic composition of the blood1, 22, 43 and 64 daysThe amount of iron isotopic label in the blood at the end of each administration period plus 14 day incorporation time will be used to calculate the absolute Iron absorption for each stabilizer level

Countries

Nigeria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026